CR7496A - Piridinoilpiperidinas como agonistas de 5- ht1f - Google Patents

Piridinoilpiperidinas como agonistas de 5- ht1f

Info

Publication number
CR7496A
CR7496A CR7496A CR7496A CR7496A CR 7496 A CR7496 A CR 7496A CR 7496 A CR7496 A CR 7496A CR 7496 A CR7496 A CR 7496A CR 7496 A CR7496 A CR 7496A
Authority
CR
Costa Rica
Prior art keywords
substituted
cycloalkyl
compounds
alkyl
synthesis
Prior art date
Application number
CR7496A
Other languages
English (en)
Inventor
Philip Cohen Michael
Timothy Kohlman Daniel
Xi Liang Sydney
Mancuso Vincent
Victor Frantz
Xu Yao-Chang
Ying Bai-Ping
Anna Piatt Zacherl De
Zhang Deyi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28791923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7496(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR7496A publication Critical patent/CR7496A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se refiere a compuestos de formula I. o sales de adicion de acidos farmaceuticamente aceptables de los mismos. Donde R1 es alquilo C1-C6 alquilo C1-C6 sustituido, cicloalquiloC3-C7, cicloalquilo C3-C7sustituido, cicloalquil-C3-C7-alquiloC1-C3, cicloalquilC3-C7 sustituido-alquilo C1-C3, fenilo, fenilo sustituido, heterociclo, o heterociclo sustituido Los compuestos de la presente invencion son utiles para activar los receptores 5-HT 1f inhibir extravasacion neuronal de proteinas y para el tratamiento o prevencion de migrana en un mamifero. Tambien se refiere a un procedimiento para la sintesis de intermedios en la sintesis de compuesos de formula I
CR7496A 2002-03-29 2004-09-24 Piridinoilpiperidinas como agonistas de 5- ht1f CR7496A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36908802P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
CR7496A true CR7496A (es) 2004-11-27

Family

ID=28791923

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7496A CR7496A (es) 2002-03-29 2004-09-24 Piridinoilpiperidinas como agonistas de 5- ht1f

Country Status (31)

Country Link
US (6) US7423050B2 (es)
EP (1) EP1492786B1 (es)
JP (2) JP4493345B2 (es)
KR (1) KR100985995B1 (es)
CN (1) CN100352817C (es)
AR (1) AR039150A1 (es)
AT (1) ATE341543T1 (es)
AU (1) AU2003224719B2 (es)
BR (1) BRPI0308495B8 (es)
CA (2) CA2478229C (es)
CR (1) CR7496A (es)
CY (1) CY1105899T1 (es)
DE (1) DE60308850T2 (es)
DK (1) DK1492786T3 (es)
EA (1) EA007966B1 (es)
EC (1) ECSP045317A (es)
EG (1) EG25226A (es)
ES (1) ES2277074T3 (es)
HR (1) HRP20040883B1 (es)
IL (1) IL163928A0 (es)
MX (1) MXPA04009497A (es)
MY (1) MY134666A (es)
NO (1) NO330394B1 (es)
NZ (1) NZ534952A (es)
PE (1) PE20030976A1 (es)
PL (1) PL210019B1 (es)
PT (1) PT1492786E (es)
TW (1) TWI263497B (es)
UA (1) UA77504C2 (es)
WO (1) WO2003084949A1 (es)
ZA (1) ZA200407666B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
BRPI0409211A (pt) 2003-04-18 2006-03-28 Lilly Co Eli composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
WO2005061439A1 (en) * 2003-12-17 2005-07-07 Eli Lilly And Company Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP2008513426A (ja) * 2004-09-20 2008-05-01 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
EP1794130A1 (en) * 2004-09-20 2007-06-13 Biolipox AB Pyrazole compounds useful in the treatment of inflammation
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EA200801108A1 (ru) * 2005-10-31 2008-10-30 Биолипокс Аб Триазолы, пригодные для лечения воспалений
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009513692A (ja) * 2005-11-01 2009-04-02 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
EP1987019B1 (en) * 2006-02-17 2012-11-28 F. Hoffmann-La Roche AG Benzoyl-piperidine derivatives as 5ht2/d3 modulators
MX2011010359A (es) * 2009-04-02 2012-02-23 Colucid Pharmaceuticals Inc Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
US8429652B2 (en) 2009-06-22 2013-04-23 Citrix Systems, Inc. Systems and methods for spillover in a multi-core system
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US20120129842A1 (en) 2010-11-18 2012-05-24 Paul Francis Jackson Bisthiazole inhibitors of pro-matrix metalloproteinase activation
CN102993086A (zh) * 2012-10-11 2013-03-27 南通市华峰化工有限责任公司 一种2，6-二溴吡啶的合成方法
CN114213393A (zh) * 2016-07-15 2022-03-22 杭州领业医药科技有限公司 一种受体激动剂的晶型及其制备方法和药物组合物
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
US10899767B2 (en) 2016-10-05 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof
WO2018085491A1 (en) * 2016-11-02 2018-05-11 Musc Foundation For Research Development 5ht1f receptor agonists and mitochondrial biogenesis
PL3551617T3 (pl) * 2016-12-06 2021-12-20 Colucid Pharmaceuticals, Inc. Kompozycje i sposoby związane z pirydynoilopiperydynowymi agonistami 5-HT<sub>1F</sub>
KR20190105015A (ko) 2017-01-13 2019-09-11 다이닛본 스미토모 세이야꾸 가부시끼가이샤 파킨슨병에 수반하는 비운동 증상의 치료약
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
CN110386918B (zh) * 2018-04-23 2020-06-09 新发药业有限公司 一种5-ht1f激动剂化合物的制备方法
CA3107145A1 (en) 2018-08-24 2020-02-27 Sunshine Lake Pharma Co., Ltd. Pyridinylmethylenepiperidine derivatives and uses thereof
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
WO2020095171A1 (en) * 2018-11-05 2020-05-14 Glenmark Life Sciences Limited, Glenmark Pharmaceuticals Limited Process for preparation of lasmiditan
ES2801774B2 (es) 2019-07-01 2022-03-30 Moehs Iberica Sl 2,2-dimetil-n-[6-(1-metil-piperidin-4-carbonil)-piridin-2-il]-propionamida, procedimiento para la preparacion de (6-amino-piridin-2-il)-(1-metil-piperidin-4-il)-metanona usando dicho compuesto y uso de dicho compuesto en la preparacion de lasmiditan
TWI829107B (zh) * 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN110981854B (zh) * 2019-09-10 2023-03-28 南京三元阳普医药科技有限公司 2-氨基-6-(1-烷基哌啶-4-羰基)吡啶类化合物的合成方法
CN114728929A (zh) * 2019-11-22 2022-07-08 广东东阳光药业有限公司 吡啶亚甲基哌啶衍生物及其用途
CN111187252B (zh) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 吡啶酰基氮杂螺庚烷衍生物及其用途
CN110845402B (zh) * 2019-11-22 2023-05-09 广东东阳光药业有限公司 吡啶亚甲基哌嗪衍生物及其用途
CN111187251B (zh) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
IT201900023937A1 (it) * 2019-12-13 2021-06-13 Olon Spa Procedimento per la preparazione di Lasmiditan e di un intermedio di sintesi
CN113045540B (zh) * 2019-12-27 2024-02-13 上海天慈国际药业有限公司 一种拉司米地坦的制备方法
EP4096662B1 (en) * 2020-01-31 2026-03-25 Alivus Life Sciences Limited Process for preparation of lasmiditan
CN113637003B (zh) * 2020-05-11 2024-03-19 鲁南制药集团股份有限公司 一种制备2-氨基-6-（哌啶-4-酰基）吡啶衍生物的方法
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
WO2022079591A1 (en) * 2020-10-14 2022-04-21 Alembic Pharmaceuticals Limited Pharmaceutical composition of lasmiditan and process of preparation thereof
CN114573555B (zh) * 2020-11-30 2026-02-17 上海天慈国际药业有限公司 一种用于治疗偏头痛的化合物的制备方法
CN114685439B (zh) * 2020-12-30 2025-07-22 鲁南制药集团股份有限公司 一种拉司米地坦的制备方法
EP4333815A1 (en) 2021-05-07 2024-03-13 Eli Lilly And Company Taste masked compostions of 2,4,6-trifluoro- n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2- ylj-benzamide hemisuccinate, and orally disentegrating tablet comprising the same
CN115594665A (zh) * 2021-07-08 2023-01-13 北京万全德众医药生物技术有限公司（Cn） 拉司米地坦的新制备方法
IT202100023861A1 (it) 2021-09-16 2023-03-16 Procos Spa Processo per la preparazione di (6-alopiridin-2-il)(1-metilpiperidin-4-il)metanone
CN113866318B (zh) * 2021-10-21 2023-07-04 佛山奕安赛医药科技有限公司 一种(6-氨基吡啶-2-基)(1-甲基哌啶-4-基)甲酮双盐酸盐的检测方法
CN116239569B (zh) * 2021-12-07 2025-11-21 山东新时代药业有限公司 一种半琥珀酸拉司米地坦晶型及其制备方法
CN116239570B (zh) * 2021-12-08 2025-11-25 山东新时代药业有限公司 一种半琥珀酸拉司米地坦新晶型
WO2023152081A1 (en) 2022-02-09 2023-08-17 Inke, S.A. Process for preparing pyridinoylpiperidines 5-ht1f agonists and salts thereof
CN116925037A (zh) * 2022-04-02 2023-10-24 山东新时代药业有限公司 一种2-氨基-6-(1-甲基哌啶-4-基羰基)吡啶的制备方法
WO2025240390A1 (en) * 2024-05-13 2025-11-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Mary1 and derivatives thereof for the treatment of mitochondrial dysfunction, vascular injury, kidney diseases, and organ aging

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US677428A (en) * 1900-04-28 1901-07-02 Chicago Handle Bar Co Steering device for bicycles.
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JPH03255426A (ja) 1990-03-06 1991-11-14 Toshiba Corp 有機非線形光学材料
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CN1184425A (zh) 1995-03-20 1998-06-10 伊莱利利公司 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
JPH11513666A (ja) 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
CZ293628B6 (cs) * 1996-03-29 2004-06-16 Pfizer Inc. Benzyl(iden)laktamové deriváty a jejich použití a farmaceutické kompozice na jejich bázi
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
KR20000035942A (ko) 1996-08-28 2000-06-26 피터 지. 스트링거 치환 1,2,3,4-테트라히드로-2-디벤조푸란아민 및2-아미노시클로헵타[ｂ]벤조푸란
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine
US5792763A (en) 1996-10-08 1998-08-11 Eli Lilly And Company Serotonin 5-HT1F agonists
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6303627B1 (en) * 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
WO2000000490A2 (en) 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
WO2000000487A1 (en) 1998-06-30 2000-01-06 Eli Lilly And Company 5-ht1f agonists
US6608079B1 (en) 1998-12-11 2003-08-19 Eli Lilly And Company Indole derivatives and their use as 5-HT1F agonists
US6777428B1 (en) * 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
KR20010102003A (ko) * 1999-02-10 2001-11-15 피터 지. 스트링거 5-ｈｔ1ｆ 효능제
CA2371784A1 (en) 1999-02-26 2000-08-31 Eli Lilly And Company 5-ht1f agonists
JP5265838B2 (ja) 2000-07-13 2013-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キラルな化合物ｉ
US6650463B2 (en) * 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
AU2003295782A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
BRPI0409211A (pt) * 2003-04-18 2006-03-28 Lilly Co Eli composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20080125432A1 (en) 2004-12-01 2008-05-29 Devgen Nv 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
KR20060067738A (ko) 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
MX2011010359A (es) 2009-04-02 2012-02-23 Colucid Pharmaceuticals Inc Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists

Also Published As

Publication number Publication date
DE60308850D1 (de) 2006-11-16
EP1492786B1 (en) 2006-10-04
TWI263497B (en) 2006-10-11
BR0308495A (pt) 2005-02-01
CN1642939A (zh) 2005-07-20
CY1105899T1 (el) 2011-02-02
JP2005530722A (ja) 2005-10-13
EG25226A (en) 2011-11-17
ES2277074T3 (es) 2007-07-01
ZA200407666B (en) 2006-02-22
PT1492786E (pt) 2007-01-31
US7423050B2 (en) 2008-09-09
BRPI0308495B1 (pt) 2015-07-07
US20080300407A1 (en) 2008-12-04
CA2694410C (en) 2013-01-29
CA2478229C (en) 2011-03-22
US20150376178A1 (en) 2015-12-31
HRP20040883B1 (en) 2012-11-30
UA77504C2 (en) 2006-12-15
US20050222206A1 (en) 2005-10-06
CA2694410A1 (en) 2003-10-16
NZ534952A (en) 2005-11-25
EA007966B1 (ru) 2007-02-27
HRP20040883A2 (en) 2004-12-31
ATE341543T1 (de) 2006-10-15
KR100985995B1 (ko) 2010-10-06
JP4493345B2 (ja) 2010-06-30
US20170044136A1 (en) 2017-02-16
DE60308850T2 (de) 2007-05-24
DK1492786T3 (da) 2007-02-12
PL372845A1 (en) 2005-08-08
TW200306186A (en) 2003-11-16
US8044207B2 (en) 2011-10-25
MY134666A (en) 2007-12-31
US8748459B2 (en) 2014-06-10
PL210019B1 (pl) 2011-11-30
IL163928A0 (en) 2005-12-18
US20120329820A1 (en) 2012-12-27
EP1492786A1 (en) 2005-01-05
US20090209563A1 (en) 2009-08-20
AU2003224719A1 (en) 2003-10-20
PE20030976A1 (es) 2003-11-12
WO2003084949A1 (en) 2003-10-16
CN100352817C (zh) 2007-12-05
JP2010159272A (ja) 2010-07-22
EA200401282A1 (ru) 2005-02-24
NO20044654L (no) 2004-10-28
HK1073464A1 (en) 2005-10-07
NO330394B1 (no) 2011-04-04
AU2003224719B2 (en) 2008-08-14
ECSP045317A (es) 2004-11-26
BRPI0308495B8 (pt) 2021-05-25
CA2478229A1 (en) 2003-10-16
KR20040094872A (ko) 2004-11-10
MXPA04009497A (es) 2005-06-08
AR039150A1 (es) 2005-02-09

Similar Documents

Publication Publication Date Title
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR066972A1 (es) Derivados azapeptidicos
AR052156A1 (es) Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
UY27918A1 (es) Derivados de benzodioxol
ATE442356T1 (de) 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
TW200744587A (en) Azaindole derivatives exhibiting PGD2 receptor antagonism
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
UY28101A1 (es) Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer
NI200900181A (es) Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos.
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
CO5690599A2 (es) Derivados de 3-(4-aminofenil) tienopirimid-4-ona como antagonistas mch r1 para el tratamiento de obesidad, diabetes, depresion y ansiedad
PA8561501A1 (es) Lactamas como antagonistas de taquiquininas
EA200700756A1 (ru) Пиримидоны
CY1109085T1 (el) Νεα αλατα
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
ECSP066415A (es) 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas
MX2024012967A (es) Derivados de piridina para el tratamiento de los trastornos psiquiatricos